Opipramol
NERVOUS SYSTEM
Also known as: opipramol dihydrochloride, opramidol
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Opipramol is a drug catalogued in DrugCentral. DrugCentral lists 4 molecular targets, including SIGMAR1, EBP and ERG2. Recorded indications include Depressive disorder.
- Molecular targets: SIGMAR1, EBP, ERG2 and CACNA1B (4 listed in DrugCentral).
- Indications: Depressive disorder.
- ATC code: N06AA05 (Non-selective monoamine reuptake inhibitors).
- Molecular formula: C23H29N3O; molecular weight 363.50 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Depressive disorder
Mechanism & targets
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sigma non-opioid intracellular receptor 1 | SIGMAR1 | unknown | Ki 9.70 |
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | EBP | unknown | Ki 7.89 |
| C-8 sterol isomerase | ERG2 | unknown | Ki 7.77 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | CACNA1B | unknown | IC50 4.62 |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N06AA05 | NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Non-selective monoamine reuptake inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| General physical health deterioration | 184.4 |
| Abnormal palmar/plantar creases | 90.3 |
| Product prescribing error | 77.0 |
| Product monitoring error | 51.1 |
| Dysmorphism | 51.1 |
| VACTERL syndrome | 40.9 |
| CADASIL | 39.9 |
| Hypoparathyroidism secondary | 39.7 |
| Fall | 39.6 |
| Hemivertebra | 38.1 |
| Foetal exposure during pregnancy | 37.9 |
| Transposition of the great vessels | 37.2 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Opipramol is on its molecule page.
| Molecular formula | C23H29N3O |
|---|---|
| Molecular weight | 363.50 g/mol |
| CAS number | 315-72-0 |
| InChIKey | YNZFUWZUGRBMHL-UHFFFAOYSA-N |
| PubChem CID | 9417 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Opipramol used for?
DrugCentral lists the following indications for Opipramol: Depressive disorder.
How does Opipramol work?
Its molecular targets in DrugCentral include SIGMAR1, EBP, ERG2 and CACNA1B.
What is the chemical formula of Opipramol?
Opipramol has the molecular formula C23H29N3O and a molecular weight of 363.50 g/mol.
Browse: all drugs starting with O · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1993 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1524185 — compound record and bioactivity
- PubChem CID 9417 — chemical identifiers
- DrugBank DB12930 — drug record
- FDA UNII D23ZXO613C — substance identity
- UniProt Q99720 (SIGMAR1) — target protein
- UniProt Q15125 (EBP) — target protein
- UniProt Q00975 (CACNA1B) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.